Metagenomi Therapeutics, Inc. Common Stock
MGXMetagenomi, Inc. (MGX) is a biotechnology company focused on the development of next-generation gene editing therapies. Leveraging its proprietary platform, the company aims to create precise, safe, and effective genetic treatment solutions for a range of genetic diseases and conditions.
Company News
Over 50 pharmaceutical companies are advancing 55+ pipeline hemophilia drugs across various clinical development stages. Key players including Novo Nordisk, Roche, Regeneron, and others are developing innovative therapies with mechanisms like FVIII mimetics, gene therapies, and factor replacement treatments. Recent developments include Novo Nordi...
Metagenomi Therapeutics announced a publication in Nature Structural & Molecular Biology highlighting MG119-28, a compact CRISPR nuclease demonstrating superior editing efficiency compared to previous compact nucleases. The nuclease showed 64% knockdown of target protein in mice via single AAV injection, supporting the company's path toward clini...
Metagenomi presented data at the ASGCT Annual Meeting 2025, showcasing advancements in its gene editing technologies, including compact nucleases for extrahepatic gene editing and CAST for site-specific integration of large therapeutic genes.
Metagenomi, a precision genetic medicines company, announced upcoming scientific presentations and provided updates on its gene editing technology and pipeline. The company highlighted positive results from a nonhuman primate study for its hemophilia A treatment and advancements in its CRISPR-associated transposase (CAST) systems.
Totus Medicines, a company developing small molecule medicines using DNA-encoded covalent library technology and AI/ML, has appointed Simon Harnest as its new Chief Financial Officer. This appointment comes as the company prepares to advance its lead covalent PI3Kα inhibitor, TOS-358, following positive Phase 1 results.
